Overview
Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis
Status:
Completed
Completed
Trial end date:
2006-07-27
2006-07-27
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Alcon ResearchTreatments:
Olopatadine Hydrochloride
Ophthalmic Solutions
Pharmaceutical Solutions
Criteria
Inclusion Criteria:- History of seasonal allergic conjunctivitis or rhinoconjunctivitis, a positive grass
antigen challenge reaction (skin test), and a positive response to grass in the
Conjunctival Allergen Challenge (CAC) model
Exclusion Criteria:
- Under 10 years of age